Reference : Identification of new accessible tumor antigens in human colon cancer by ex vivo prot...
Scientific journals : Article
Human health sciences : Oncology
Life sciences : Biotechnology
Life sciences : Anatomy (cytology, histology, embryology...) & physiology
http://hdl.handle.net/2268/4732
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis.
English
Conrotto, Paolo [> > > >]
Roesli, Cristof [> > > >]
Rybak, Jascha [> > > >]
Kischel, Philippe mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >]
Waltregny, David mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases - Département des sciences biomédicales et précliniques >]
Neri, Dario [> > > >]
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire - Labo de recherche sur les métastases >]
2008
International Journal of Cancer = Journal International du Cancer
Wiley Liss, Inc.
123
12
2856-2864
Yes (verified by ORBi)
International
0020-7136
1097-0215
New York
NY
[en] colorectal cancer ; proteomics ; biomarkers ; tumor targeting ; immunotherapy
[en] One of the most promising new strategies for the development of efficacious cancer therapies relies on the targeted delivery of biopharmaceutical to the tumor environment by the use of selective and specific antibodies. The identification of accessible perivascular proteins selectively overexpressed in cancer tissue may facilitate the development of antibody-based biopharmaceutical administration. This approach is potentially highly selective and specific, combining the presence of tumor biomarkers readily accessible from the blood vessels and the high rate of angiogenesis characteristic of cancer tissues. We performed ex vivo perfusions of surgically resected human colon cancer using a reactive ester derivative of biotin, thus achieving a selective covalent modification of accessible proteins in vascular structures and stroma. After extraction and purification, biotinylated proteins were digested and the resulting peptides submitted to a comparative mass spectrometry-based proteomic analysis, revealing quantitative differences between normal and cancer colon. Sixty-seven of the total 367 proteins identified were found to be preferentially expressed at the tumor site. We generated human monoclonal antibodies against 2 potential tumor targets, NGAL and GW112, and we proved their selective expression in cancer colon and not or barely in healthy tissues. This article presents the first proteomic analysis of human colorectal cancer structures readily accessible from the tumor vasculature, revealing the overexpression of novel tumor antigens which may serve as selective targets for antibody-based imaging and therapeutic biomolecular strategies. (c) 2008 Wiley-Liss, Inc.
Giga-Cancer
Swiss National Science Foundation ; The Gebert-Ruef Foundation ; The Schweizer Krebsliga ; The ETH Zurich ; EU projects STROMA ; FLUORMMPI ; IMMUNOPDT ; Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; TELEVIE ; Centre Anti-Cancéreux de Liège ; UICC
Researchers
http://hdl.handle.net/2268/4732
also: http://hdl.handle.net/2268/33872
10.1002/ijc.23861

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
CONROTTO INT J CANCER 2008.pdfNo commentaryPublisher postprint3.3 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.